All posts by medical

Arcutis Announces Appointment of Terrie Curran to Board of Directors – GlobeNewswire

WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that Terrie Curranhas been appointed to the Arcutis Board of Directors effective Nov. 2, 2020, and that Alexander Asam, Ph.D. has decided to step down from the Board.

We are tremendously grateful for Alexanders contributions to Arcutis, commented Patrick Heron, Chairman of the Arcutis Board of Directors. His thoughtful counsel and leadership were instrumental in our recent progress, particularly our two recent very successful public financings. While we will miss his guidance, we wish him well in his future endeavors.

We are absolutely delighted to welcome Terrie to the Arcutis Board, said Frank Watanabe, Arcutis President and Chief Executive Officer. She is an exceptionally talented biopharmaceutical executive with over 20 years of industry experience in product commercialization. With her extensive experience launching and successfully commercializing innovative products in the dermatology segment, she is uniquely positioned to help Arcutis in its next stage of development, particularly in light of the upcoming data from our pivotal Phase 3 trials and potential NDA submission next year.

I am delighted to join the Arcutis board at this exciting time, said Terrie Curran. The Companys lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. I look forward to contributing my expertise, specifically with commercialization planning and execution, to help them build a leading dermatology company.

Ms. Curran is CEO and President at Phathom Pharmaceuticals (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases. Prior to this, she was the former President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene. She joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA for moderate-to-severe plaque psoriasis. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Womens Health at Merck & Co. Ms. Curran holds graduate and bachelors degrees from the University of Technology Sydney.

About Arcutis - Bioscience, applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions. The Company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The Companys lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit http://www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding data from the pivotal Phase 3 trials; the potential NDA submission next year; the potential for topical roflumilast to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis; and the potential for Arcutis to become a leading dermatology company. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on August 11, 2020, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

Read the original here:
Arcutis Announces Appointment of Terrie Curran to Board of Directors - GlobeNewswire

Canadian scientists find markers in blood they believe are linked to severe COVID-19 – National Observer

Canadian immunologists say theyre finding telltale markers in patients' blood that help predict the severity of COVID-19 and could lead to more targeted treatments.

David Kelvin, a Dalhousie University professor of immunology, is co-author of a study that draws links between severity of the illness and the presence of large amounts of the virus's genetic material ribonucleic acid, or RNA in blood samples.

He and Spanish scientist Jesus Bermejo-Martin of the Institute of Biomedical Investigation of Salamanca led a group of 36 medical researchers tracking patients coming into Spanish hospital wards and ERs, and looking for about 30 so-called "biomarkers in their blood plasma.

The work occurred during the first wave of the pandemic in the spring.

Though less publicized than research on vaccines, biomarkers are seen as key to tracking and predicting illness, and they can identify which proteins are being released that prevent the immune system from coping.

The study, which has been published online and is currently in the final stages of peer review for the journal Critical Care, concludes that the presence of the virus's RNA in blood is "associated to critical illness."

Kelvin says the work could lead to partnering with a pharmaceutical firm to develop standard and rapid blood-testing looking for the genetic marker in patients who test positive.

"A test is what we're hoping for," he said in an interview this week. "We need to develop ways to quickly know who should be placed in a ward, who should go in (intensive care) and who is well enough to go back home."

While North American hospitals often do test for the presence of the viruss genetic material in the blood of severely ill COVID-19 patients, Kelvin says more rapid, standardized tests are needed for patients when they arrive in hospital.

"We're facing a huge surge in patients, and there are a limited number of beds," he said. "If we want to allocate those beds, we should tie them to those who have this genetic material circulating in their blood."

The article says the Spanish-based study is among the largest of its kind in the world to date, with 250 patients included 50 outpatients, 100 patients hospitalized in various wards and 100 critically ill patients. Blood samples were collected within 24 hours of patients being admitted, with a series of followup tests.

The paper found 78 per cent of critically ill patients had the genetic material as a biomarker, compared to just a quarter of the general ward patients and two per cent of outpatients.

Kelvin said his study also noted the presence of three molecules associated with repressing the immune system in the critically ill patients studied, a finding that other scientists can pursue.

There seemed to be a link between the trio of molecules Interleukin-10, Interleukin-1 RA and PDL-1 and the presence of the virus's genetic material in the blood, he said. The molecules occur naturally in the body and are used clinically to treat autoimmune diseases.

The detection of the molecules in critically sick patients comes on the heels of similar findings by British scientists.

Immunologist Mark Cameron, who worked with Kelvin studying the 2003 SARS outbreak in Toronto, says the findings are helpful on several levels.

In the short term, the linking of the virus's RNA with critical illness helps clinicians in diagnosing severity of the illness, said Cameron, a Canadian based at Case Western Reserve University in Cleveland, Ohio.

Meanwhile, identifying proteins that signal the immune system isn't reacting properly can lead to targeted therapies, he added.

"By testing for and identifying biomarkers, you can then find treatments or drugs that can rebalance our immune system, Cameron said in an interview.

If we find a biomarker that's up or down and is associated with good or bad outcomes, you have something you can change that can push you towards health rather than worsening illness," he said.

Cameron said often the main treatment for severe COVID-19 is steroids, but his hope is the biomarkers will allow for more precise therapies.

"A steroid is like a sledgehammer . . . . It tamps down the entire immune response and may decrease the things we need in our immune system to fight the virus. So, you want more specific treatments," he said.

His team is studying the early biomarkers present in 50 patients who have just been infected in nursing homes in Cleveland.

Like Kelvin, his early findings also show the presence of the RNA of the virus in patients who are ill, though he didn't quantify the amounts.

Cameron said testing systems used in the study are extremely precise, but the goal will be to create cheaper methods that can produce results in minutes or hours.

Asked if the work will become irrelevant if a vaccine is found, Cameron said the study of biomarkers will remain crucial in years to come to monitor COVID-19 in patients and target their treatment.

"This will be needed five months from now, and five years from now," he said.

This report by The Canadian Press was first published Oct. 30, 2020.

Don't miss out on the latest news

Go here to see the original:
Canadian scientists find markers in blood they believe are linked to severe COVID-19 - National Observer

Horizon Therapeutics plc Names Karin Rosn, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer – Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosn, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer.

We are thrilled to welcome Karin to Horizon during this transformative time in our companys growth, said Walbert. We have made significant progress during the last three years in building a strong R&D organization and a diversified pipeline. We are confident that Karins ability to build and lead cross-functional teams, clinical development experience and therapeutic area expertise, will contribute to solidifying our position as a leading rare disease biopharmaceutical company.

Dr. Rosn is an accomplished life sciences executive and physician with nearly three decades of experience that includes directing biologic clinical research and development and building, leading and successfully launching multiple novel medicines in the United States and globally. Prior to Horizon, she was senior vice president, U.S. medical affairs at GlaxoSmithKline, where she led a team of more than 300 physicians and medical professionals in disease areas including immunology, respiratory and inflammation.

I have focused my entire career on collaborating with diverse teams to address complex scientific problems that result in treatments for patients in need, said Dr. Rosn. There is much work to be done in the research and development of medicines for rare diseases and I applaud Horizons continued commitment to this space. The companys evolution during the last decade to bring therapies to the most underserved communities is inspiring and I look forward to leading this accomplished R&D organization.

Prior to GlaxoSmithKline, Dr. Rosn was senior vice president, U.S. and global medical affairs at Aimmune Therapeutics, Inc. as well as a member of the clinical development leadership team working on the Phase 2b-3/4 clinical programs and U.S. FDA and European Medicines Agency filing strategies. Prior to Aimmune, Dr. Rosn was therapeutic area head, immunology, at Genentech, a member of the Roche Group. During her tenure at Genentech, she also served as lead medical director responsible for developing Phase 2-3 clinical programs for multiple biologics in the areas of immunology, respiratory, allergy and dermatology.

Dr. Rosn received her medical degree and doctorate from Lund University in Lund, Sweden.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit http://www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

See the article here:
Horizon Therapeutics plc Names Karin Rosn, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer - Business Wire

Transforming coronavirus proteins into nanoparticles may hold the key to an effective COVID-19 vaccine – McGill Newsroom

Changing makeup of a specific protein has the potential to neutralize the virus

Researchers from McGill University are part of an international team led by the University of Buffalo, which has discovered a technique that could help increase the effectiveness of vaccines against SARS-CoV-2, the virus that causes COVID-19. The groups study was published recently online in the journal Advanced Materials.

COVID-19 has caused a disruptive global pandemic, infecting at least 40 million and causing more than 1 million deaths worldwide. Since it began spreading in early 2020, biomedical researchers have been in active pursuit of an effective vaccine. Now, researchers suggest that one approach that may be effective is designing vaccines that partially mimic the structure of the virus.

The critical contribution of this paper is that it opens a new approach for the development of a COVID-19 vaccine, says Joaquin Ortega, a professor in the Department of Anatomy and Cell Biology at McGill University and a co-author of the study. We found that presenting one of the most important antigens in the SARS-CoV-2 virus, the receptor-binding domain (RBD), in the surface of nanodevices called liposomes, which are used extensively for drug delivery in cancer, induces a much stronger antibody response than when the RBD antigen is administered by itself. The researchers report the creation of a flexible COVID-19 vaccine development platform - a new approach that works efficiently when adsorbing the RBD antigen to the liposome's surface but can be extended to other antigens as well. We still do not know which of the viral antigens are causing the most robust immunity and would therefore be most beneficial for vaccine development , notes Prof. Mike Strauss, Assistant Professor in the Department of Anatomy and Cell Biology at McGill, and a co-author on the paper. Besides, specific antigens may generate adverse effects, including lung tissue damage, a significant issue encountered in the past during the attempts to develop vaccines against SARS-CoV-1 in the 2000s. Having a flexible platform for vaccine development, such as the one described in our paper, allows us to create a-la-carte vaccines that only incorporate those antigens triggering a beneficial immune response but excluding those responsible for adverse effects.

Leveraging McGills advanced microscopes for vaccine platform development

McGills contribution to this vaccine platform's development was in the structural characterization of the nanoparticles used to deliver the antigen to the immune system, using the Facility for Electron Microscopy Research (FEMR) at McGill, the largest and most versatile cryo-electron microscope platform in Canada. This facility houses the most advanced and fastest electron microscopes in the world, producing extremely high resolution imaged that are essential for the characterization of nanoparticles, such as those used as antigen carriers in these vaccines. Cryo-electron microscopy images constitute the gold standard technique to ensure the liposomes carrying the antigens in the vaccine have the desired size and structure to induce a robust immune response.

Professors Strauss and Ortega, who are respectively the FEMR Technical Director and Scientific Director, loaded approximately three microlitres of the vaccine mixture into the Titan Krios microscope at FEMR. In the span of one hour, the Krios microscope produced over 300 images of the small lipidic vesicles contained on the vaccine. These images verified that the RBD antigen was being adsorbed in the lipidic surface of the liposome, which is the optimal location for antigen presentation to the immune system.

FEMR cryo-electron microscopy images showing the structure and location of the RBD antigen in the surface of the lipidic vesicles was essential data for the development of this SARS-CoV-2 vaccine, says Prof. Ortega. There is no other method that allows for the direct visualization of the antigen adsorbed to the liposomes' surface. Other biophysical methods can produce an indirect measurement suggesting the antigens may have been incorporated. Still, only cryo-electron microscopy is capable of visualizing these antigens on the surface of the liposomes directly.

While the paper shows that this SARS-CoV-2 vaccine induces a robust immune response in mice animal models, the researchers say that like any other vaccine, it must undergo extensive additional testing and clinical trials before it can be administered to human communities. They also note that the evidence presented in this study that shows the RBD antigen benefits from being in particle format could help inform future vaccine design that targets this specific antigen.

Authors on the study include Jonathan Lovell, Wei-Chiao Huang, Shiqi Zhou, Xuedan Heand Moustafa T. Mabrouk, all from the University of Buffalo Department of Biomedical Engineering; Kevin Chiemand Luis Martinez-Sobrido, both from Texas Biomedical Research Institute; Ruth H. Nissly, Ian M. Bird and Suresh V. Kuchipudi,all from the Animal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences at Pennsylvania State University; Mike Straussand Joaquin Ortegafrom the Department of Anatomy and Cell Biology at McGill University; Suryaprakash Sambharafrom the Immunology and Pathogenesis Branch of the U.S. Centers for Disease Control and Prevention; Elizabeth A. Wohlfertfrom the Department of Microbiology and Immunology at UB; and Bruce A. Davidsonfrom the Department of Anesthesiology and the Department of Pathology and Anatomical Sciences at UB.

The study was supported by the U.S. National Institutes of Health, the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), and the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, Quebec Government and McGill University.

Read more here:
Transforming coronavirus proteins into nanoparticles may hold the key to an effective COVID-19 vaccine - McGill Newsroom

Kentucky Neuroscience Institute Leading the Way in New Treatment Improving Quality of Life for Complex Epilepsy Patients – UKNow

LEXINGTON, Ky. (Nov.4, 2020) In America,3.5 million people have epilepsy. Approximately onein 26 people in the United States will develop epilepsy at some point in their lifetime. In Kentucky, more than 2% of the population is living with this neurologic condition characterized by unpredictable seizures.

Epilepsy has numerous physical and emotional costs. Patients can experience problems keeping up in school or at work, depression and/or social isolation, physical injury during a seizure, and can even die from a seizure. They may not be allowed to drive, play sports, or have other restrictions that impact their professional or personal lives.

Despite the development of several new anti-seizure medications or anti-epileptic drugs over the past couple of decades, approximately 30-40% of epilepsy patients remain refractory or resistant to medical treatment.

Vivian Albrektsen falls into that category. The 42-year-old, who is legally blind, was having up to 25 seizures in one day and had taken more than 10 different medications. Her seizure focus could not be clearly localized and she was not amenable to resective epilepsy surgery. Vivian would experience brief honeymoon periods after trying a new medication.

What happens with me is Ill get a good seizure medication," she said."It will work for maybe six months and then my brain talks to itself and says you know this has been working we need to try something else.

Vivian has been seeing Dr. Meriem Bensalem-Owen, director of UK HealthCares Epilepsy Program, for almost a decade after receiving her epilepsy diagnosis. In 2018, Bensalem-Owen and her team were thrilled when the Food and Drug Administration approved the utilization of Deep Brain Stimulation (DBS) devices as a treatment for epilepsy giving them a new option to provide some hope for patients like Vivian.

DBS has been a treatment option for other neurological disorders for several years. UK HealthCare neurosurgeon Dr. Craig van Horne has been a leader in using DBS treatment for Parkinsons disease. Bensalem-Owen says the principle of DBS for movement disorders like Parkinsons disease and epilepsy is the same however the targets are different.

DBS implantation requires two surgeries:one to implant the generatorand a secondto implant leadsthat go from the chest and neck into the brain. The location of where the leadsare implanted is how Bensalem-Owen says DBS for epilepsy differs from DBS used for other disorders. The goal of DBS for epilepsy is to disrupt certain electrical activity in the brain to control seizures. Over time,neuromodulation can be achieved. This meansDBS therapy is designed to change (modulate) how brain cells work by giving electrical stimulation to brain areas involved in the patients seizures.

Brain cells are all the time misfiring and firing. When the firing becomes synchronized it can cause seizures. This device disrupts that synchrony or harmony, saidBensalem-Owen. When telling patients about the treatment she uses, she compares it to theconductor of an orchestra. We disrupt the conductor with small electrical impulses so the right directions cannot be given to the whole orchestra.

Dr. van Horne successfully implanted one of Dr. Bensalem-Owens patients with the first DBS device in Kentucky shortly after getting FDA approval. Since then six others have received a DBS implant at UK HealthCare, including Vivian. This represents the highest number of epilepsy patients implanted with this device in Kentucky.

The combination of medication and DBS allowed Vivian to go several months seizure-free.

Before the DBS it was like a revolving door every several months of changing medications. I was getting tired of it, said Vivian. She credits Dr. Bensalem-Owen and UK HealthCare with saving her life.

Bensalem-Owen says seeing a patient go several months without a seizure is not consistently observed with DBS. She says those that qualify for this type of treatment are the most difficult to get seizures under control with medications and who cannot have removal of the part of the brain that causes seizures to happen.

Sometimes we dont achieve seizure freedom despite our best efforts," she said. "The goal then is to really attempt to improve the quality of life and the seizure burden.

Working with patients like Vivian - who have endured years of changes in medications, surgeries, and side effects - to find the right treatment plan isnt always easy, but it is a job that Bensalem-Owen and her team take great pride in.

We are here to support our patients, some of them are very complex," she said."Some of them are difficult not just for the type of their epilepsy but because of co-existing medical conditions and difficult social situations. They dont get to choose how they are. My colleagues and I like the challenge and we are here to help everyone with difficult to control epilepsy.

Bensalem-Owen says so far what they are seeing in the seven DBS device recipients at UK is promising.

Overall, we see an improvement in frequency, severityand recovery from the seizures,she said, noting thatbeing the first in the state to successfully implant an epilepsy patient and also a leader in Kentucky is a great honor. We had these patients just waiting for something to happen with new medication options, or we tried epilepsy surgery and it failed or they werent eligible. So, then it was like what do we do now? We would just wait for the next thing to come up. For us, this is an addition to our toolbox. We are thrilled to have it because we want to do all we can to help our patients have a better quality of life, and to not live in fear of injuries or death from seizures.

--

DBS treatment can only be done in an accredited National Association of Epilepsy Centers (NAEC)Level 4 epilepsy centers. UK HealthCare Kentucky Neuroscience Institute is proud to maintain a Level 4 NAEC Accreditation the highest rating by the National Association of Epilepsy Centers. UK HealthCare is the only Level 4 epilepsy center in the greater Lexington area.

See more here:
Kentucky Neuroscience Institute Leading the Way in New Treatment Improving Quality of Life for Complex Epilepsy Patients - UKNow

Neuroscience Sweden is starting to study psychedels in the treatment of depression: the results could be revolutionary – Pledge Times

This is one of the most significant things that has happened in psychiatry in the last 40 years if previous research results prove to be correct in a clinical trial, the researcher says.

In Sweden The Karolinska Institut will start this fall research, which aims to investigate the effect of psilocybin in the treatment of depression.

Psilocybin is a psychedelic substance that causes aberrant, dreamy states of consciousness. It occurs naturally in some fungi. This is the first clinical trial of psychedelics in Sweden.

.

Read more:
Neuroscience Sweden is starting to study psychedels in the treatment of depression: the results could be revolutionary - Pledge Times

Neuroscience Antibody or Research Reagents Market to Witness a Pronounce Growth – News by aeresearch

A new research study has been presented offering a comprehensive analysis on the Global Neuroscience Antibody or Research Reagents market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major Neuroscience Antibody or Research Reagents market aspects with expert opinion on current market status along with historic data. Neuroscience Antibody or Research Reagents Industry report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, revenues, market shares, business strategies, top regions, demand, and developments.

The Neuroscience Antibody or Research Reagents market report contains an extensive analysis of this industry space and provides crucial insights regarding the major factors that are impacting the remuneration graph as well as fueling the industry growth. The study also offers a granular assessment of the regional spectrum alongside regulatory outlook of this market space. Moreover, the document measures the factors that are positively influencing the market outlook as well as presents a detailed SWOT analysis. Information such as limitations & restraints faced by new entrants and market majors alongside their individual effect on the growth rate of the companies is enlisted. The research also elaborates on the impact of COVID-19 on future remuneration and growth avenues of the market.

Highlighting the competitive framework of Neuroscience Antibody or Research Reagents market:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/346200

From the regional point of view of Neuroscience Antibody or Research Reagents market:

Additional data emphasized in the Neuroscience Antibody or Research Reagents market report:

Years considered for this report:

Key Questions Answered In this Report:

What is the overall Neuroscience Antibody or Research Reagents market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?

Which region would have high demand for product in the upcoming years?

What are the factors driving the growth of the Neuroscience Antibody or Research Reagents market?

Which sub-market will make the most significant contribution to the market?

What are the Neuroscience Antibody or Research Reagents market opportunities for existing and entry-level players?

What are various long-term and short-term strategies adopted by the market players?

What are the key business strategies being adopted by new entrants in the Neuroscience Antibody or Research Reagents market?

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/346200

More:
Neuroscience Antibody or Research Reagents Market to Witness a Pronounce Growth - News by aeresearch

Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester – Black Enterprise

Dr. Monique Mendes has become the first Black woman to receive a Ph.D. in neuroscience from the University of Rochester. The Jamaican-born, first-generation college graduate says the announcement came as a shock to her, not even realizing she had done so until informed.

I didnt know I was the first Black woman, but Im excited, said Mendes to Diversity Education. I feel empowered; I really want other students in the Rochester city schools, just around Rochester that are Black, who are people of color that know that this is possible and that they can pursue a Ph.D. in neuroscience.

Her desire to obtain her degree came after she became apart of the McNair Scholars Program at the University of Florida, a program designed to help undergraduate students from low-income and marginalized backgrounds offering financial assistance in addition to mentorship to help them prepare for their doctoral degree. From there, her interest grew and she became more immersed in studying the complexities of the brain, hoping to establish a career in neuroscience.

Mendes says her love of science goes even further back from childhood. My love for science began as a small child in Jamaica, says Mendes to the universitys alumni network. I was always the one bringing in my science projects early.

She hopes that she can encourage other young Black girls to get into the STEM field, stressing the importance of providing an environment to foster curiosity in the field. I would say create an environment that is not only diverse but inclusive and also paying attention to the cultures so that Black women can feel that this is a place for them, she says. There is a seat at the table. I just think thats probably the most important thing.

The news comes as the STEM field becomes more diverse as people from underserved backgrounds gain access through various initiatives to diversify the field.

More:
Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester - Black Enterprise

Mouse Studies Link Some Autism to Brain Cells That Guide Sociability and Platonic Love – Technology Networks

Johns Hopkins Medicine researchers report that new experiments with genetically engineered mice have found clear connections among a range of autism types and abnormalities in brain cells whose chemical output forges platonic (non-sexual) feelings of love and sociability.

The findings, the researchers say, could eventually fuel the development of autism therapies that target disease symptoms spurred on by abnormalities in parvocellular oxytocin neurons, which are brain cells in the hypothalamus of mammals.

A report on the experiments was published online Oct. 27 in Neuron.

The investigators pursued evidence of the connections because of long-known variations in forms and symptoms of autism spectrum disorders, and because those with Fragile X -- an inherited disorder that occurs in one in 4,000 males and one in 6,000 females -- frequently is characterized by the inability to form close social bonds.

"Autism is defined by impaired social behaviors, but not all social behaviors are the same," says Gl Dlen, M.D., Ph.D., associate professor of neuroscience at the Johns Hopkins University School of Medicine. "People with autism generally have less difficulty with developing very close, family bonds than with friendships. Our experiments provide evidence that these two types of affection are encoded by different types of oxytocin neurons, and that disruption of one of these types of neurons is responsible for the characteristic social impairments seen in autism."

For more than a century, Dlen says, scientists have known there are two types of neurons in the hypothalamus. The neurons release the so-called "love hormone" oxytocin, which induces contractions during childbirth, reduces stress and fosters bonding among animals across mammalian species, including humans.

A magnocellular oxytocin neuron, which is one type of oxytocin-releasing neuron, releases huge quantities of oxytocin to the brain and body -- as much as 500 times or more than is released by parvocellular oxytocin neurons, which limit their scope and avoid flooding the body with all-consuming feelings of love.

As their name suggests, magnocellular oxytocin neurons are larger than other neurons and can send their arm-like axons beyond the blood-brain barrier. Among their functions, magnocellular oxytocin neurons stir filial love -- what Dlen calls "mad love" -- and bonding between infants and mothers, and between sexual partners.

Dlen's research shows that parvocellular oxytocin neurons, which comes from the Greek word "parvo" or "small" -- also encode social behaviors, but a different kind than the magnocellular neurons encode. While magnocellular oxytocin neurons encode social behaviors related to reproduction (pair bonding and parental bonding), parvocellular oxytocin neurons encode social behaviors related to what Dlen calls "love in moderation," or the platonic love that is important to communities (friends and colleagues).

To study if and how autism symptoms are associated with disruptions in either or both of magnocellular and parvocellular neurons, Dlen and her team first genetically engineered mice to glow a fluorescent light in all oxytocin neurons, magno and parvo. Then, knowing that magnocellular neurons project their axons and chemicals beyond the blood/brain barrier, the research team used dyes that stay within the barrier to mark only the parvocellular neurons -- which are rarer and harder to detect, as well as smaller in size.

Next, Dlen enlisted the help of Johns Hopkins scientist Loyal Goff, Ph.D., an expert in charting the genetic profile of individual cells. The technique, called single cell sequencing, specifically reads an individual cell's RNA -- a genetic cousin to DNA -- which indicates how the cell's genetic code is being read and which proteins are being produced. The way our genetic code is read makes one cell type different from another.

"This study is a comprehensive characterization of two types of closely-related neurons involved in the regulation of social behavior," says Goff, assistant professor of genetic medicine at the Johns Hopkins University School of Medicine. "One of the things that makes this study so unique is the multi-modal aspect of this characterization; relating anatomical, morphological, electrophysiological, transcriptional, genetic, and behavioral features to fully define the relevant and important differences between these two types of neurons."

The research team used single cell sequencing and other gene-tracking tools and techniques to ensure that the subpopulations of magnocellular and parvocellular neurons were, indeed, distinct, so that they could genetically alter each group to determine if a change would induce autism-like behaviors in mice. What the researchers measured included how much the mice liked their social interactions and how much they preferred things associated with those social interactions (such as bedding).

To re-create a model of autism in mice, the scientists turned to the FMR1 gene, which is linked to Fragile X, an inherited disorder characterized by intellectual disability, but also one of the most commonly identified causes of autism, occurring in about five percent of people with the condition.

In humans, the FMR1 gene is silenced through a cellular process that adds chemicals called methyl groups to the gene. This same process does not occur in mice, so to replicate the FMR1 gene abnormality, the scientists genetically engineered the mice to have no functioning FMR1 gene either throughout the brain or only in parvocellular neurons.

The researchers studied how mice without FMR1 valued the rewards from forming a social bond with an adult female mouse serving as a surrogate parent. These mice learned to like bedding associated with the surrogate parent, but not bedding associated with social interactions with peer mice -- evidence that mutations in genes that cause autism selectively disrupt platonic love, but spare filial love.

When the scientists deleted the FMR1 gene in parvocellular cells only, not magnocellular cells, the mice had the same reaction: intact affinity for things associated with their surrogate parent, compared with things associated with peer mice. The scientists found no such preference in mice lacking FMR1 in oxytocin magnocellular cells.

In a further set of experiments to pin down the specificity of their findings with the oxytocin-producing neurons, the scientists studied how certain genes linked to risk for autism were turned on or off, or expressed, among the two types of oxytocin neurons. They found that significantly more autism risk genes had higher expression levels in parvocellular neurons compared with magnocellular neurons. However, when the scientists looked at genes for schizophrenia, Alzheimer's disease and diabetes, there were no such differences in gene expression between the two oxytocin neuron types.

"This tells us that the difference we are seeing between the two types of oxytocin neurons relates to the disease that is characterized by impaired social behaviors, but not diseases where this behavior is not a defining symptom," says Dlen.

She also notes, "What may be happening in the brain is that even though all brain cells may carry a particular mutation associated with autism, some neurons are more vulnerable to the symptoms related to social bonding."

Dlen plans to conduct similar studies on genes associated with other types of autism. She says her work may indicate that drugs currently being tested for autism -- such as intranasal oxytocin -- could prove ineffective because the treatments target magnocellular neurons, which the new study indicates is not central to the disease. Instead, she says, their evidence suggests that parvocellular oxytocin neurons should be the focus of drug development for autism.

Reference:Connie Jiang, Loyal A. Goff, Gl Dlen et al. Parallel Social Information Processing Circuits Are Differentially Impacted in Autism. Neuron, 2020; DOI: 10.1016/j.neuron.2020.10.002

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Mouse Studies Link Some Autism to Brain Cells That Guide Sociability and Platonic Love - Technology Networks

Anxious About Election Results? Here’s What’s Happening in Your Brain as You Wait – Smithsonian Magazine

If youre feeling nervous about the looming U.S. election, and results that may take longer than a single day to resolve, youre not alone.

I joked with my friends that I wished someone would, like, knock me over the head on election morning and wake me up when the decision is made, says Kate Sweeny, a professor of psychology at the University of California, Riverside (UCR).

Sweeny isnt your average anxious voter. She has devoted a big part of her career to studying how humans deal with uncertainty as they await the outcomes of events they deem important.

Evolutionarily, anxiety serves a purpose. Its a blaring alarm inside your head that something badlegitimately dangerouscould soon occur, and that you should try to prevent it, or at least prepare for it. But sometimes, that response goes haywire. And amid uncertainty, our brains have an especially hard time calming down.

Our data very consistently show that over basically every waiting period weve ever studied, that people get more worried, and they sort of try to cope more frantically in those moments of truth, says Sweeny, who is the principal investigator of UCRs Life Events Lab.

Waiting for results from tests, elections or anything else with an unclear outcome may feel like a special kind of torment. And not everyone responds to different waiting scenarios in the same way. Time might even seem to pass differently. Using brain imaging techniques, scientists have found that the anxiety surrounding uncertainty taps into the same brain circuitry as fear of definite threats. And with an understanding of the neuroscience behind anxiety, scientists have come up with strategies you can use to help restore a sense of calm and emotional regulation.

Researchers like Sweeny who have studied anxiety among voters have noticed some trends.

In a 2019 study in Motivation and Emotion, Sweeny and Kyle Rankin, a graduate student at UCR, surveyed 699 Americans who voted in the 2016 U.S. presidential election and 376 citizens who voted in the 2018 midterms. They found that voters who viewed the election as more important, those more politically engaged and those who think waiting in general is difficult, said they worried more about the election results. Interestingly, individuals level of media exposure was not significantly linked to more worry.

Not all waiting and worrying about the uncertain future is alike, however. Aspiring lawyers, for example, spend a grueling limbo periodin California, its four monthsbefore receiving scores from the bar exam. Ph.D students may have an even longer, agonizing experience searching and waiting for academic positions. And as elections approach, anticipation builds among those deeply concerned with who will lead their community, their state or their country.

These groups do not necessarily respond similarly in terms of their emotions and health behaviors while awaiting news, according to a 2019 study in Psychology and Health by Sweeny and Jennifer Howell, a health psychology researcher at University of California, Merced. Regardless of which candidate they supported, voters who were more worried about the presidential election results in 2016 tended to report drinking more alcohol than those who were not as worried. The bar exam takers showed the same pattern, but the PhD students did not. More research is needed to explore the consistency, and to check for a possible causal relationship between anxiety about uncertain news and behaviors such as alcohol consumption.

Now, Sweeny is looking at a new, timely cohort446 participants voting in the 2020 U.S. presidential election, among whom 242 are voting for former Vice President Joe Biden, 182 for President Donald Trump and 22 for a third party. Unpublished, preliminary data from this ongoing survey effort suggest that Biden supporters report feeling more anxious than Trump supporters. Sweeny has not formally delved into why.

But its no secret that amid the disruptions to daily life amid the Covid-19 pandemic and uncertainty about the fate of their nation, many Americans are on edge.

Now, the elections are something like the anti-Christmas, because people are dreading it, says Marc Wittmann, author of Felt Time: The Psychology of How We Perceive Time and a neuropsychologist at the Institute for Frontier Areas of Psychology and Mental Health in Freiburg, Germany.

Waiting for an event you are focusing on can actually mess with your sense of time, Wittmanns research has found. In one of his studies, published in April in Acta Psychologica, subjects were told to wait in a room while the experiment was getting set up. That story was a decoy; the experiment was actually studying their perceptions of waiting over a period of seven-and-a-half minutes. When participants were asked to rate their experience, those who are usually impulsive, or who felt the most boredom and other negative emotions, overestimated the amount of time that passed.

So what is going on in the brain when you are anxious about something like your favored political candidate losing an election, and the uncertain negative consequences that may follow?

When it comes to a certain, imminent threat, such as a car racing toward you as you cross a street, neuroscientists often talk about the fight or flight response, that impulse we have to either combat a threat or run away from it. The brains key emotional center or limbic system, which includes structures called the amygdala and hippocampus, activates this response through rapid cell firing.

Hormones such as cortisol and adrenaline flood the bloodstream, which might make you sweat and your heart beat faster as your muscles engage, to prepare your body to move you to safety. But this is also what happens during heightened anxiety or a full-on panic attack, which can be triggered by a non-physical threat.

When this emotional center takes over, the front part of the brain, called the prefrontal cortex, takes the backseat, says Nii Addy, associate professor of psychiatry and of cellular and molecular physiology at Yale University. The prefrontal cortex is responsible for emotional regulation and decision-making. In situations with elements of uncertainty, such as a possible but unidentified threat, the limbic system kicks into high gear.

With more certainty theres more of that emotional control that we have, he says. Once we get toward uncertainty, those other areas of the brain take over to try to move us out of an uncertain situation, into a state where we are more certain, Addy says.

Scientists once thought of fear and anxiety as having distinct brain circuitry. Fear refers to intense, fleeting reactions to imminent and clear threatsthat flight or fight response. Anxiety is more about feeling heightened arousal or vigilance in response to uncertain or diffuse threats. Even Sigmund Freud considered fear and anxiety as different phenomena, says University of Maryland neuroscientist Alexander Shackman.

But a recent study in the Journal of Neuroscience supports the idea that the neural circuitry behind fear and anxiety are connected. The amygdala, that almond-shaped structure in the brains emotional center, has long been associated with a response to certain danger. A neighboring region called the bed nucleus of the stria terminalis, associated with anxiety, is part of the same network reacting to certain and uncertain threats, Shackman and colleagues find.

The researchers looked at subjects' brains in a functional magnetic resonance imaging (fMRI) scanner as they awaited a painful (though harmless) electric shock combined with the presentation of an unsavory image, such as a picture of a mutilated body, at the same time as a sound, such as a scream. To simulate waiting for a certain threat, experimenters gave participants a 3, 2, 1 countdown before an unpleasant shock-image-sound combination. Other subjects first viewed a random string of numbers, which created uncertainty as to when the icky stimuli would arrive.

Both threat scenarios appeared to activate the same network in the brain, strengthening the case that fear and anxiety should not be thought of as biologically separate.

If they were totally different, you would have to develop totally different biological treatments, Shackman says. To the degree that they partially overlap, you can start to contemplate broad-spectrum biological interventions that would help with extreme fear and extreme anxiety.

This is just one neuroimaging study and only 99 subjects participated. And in real life, no one barrages you with random numbers before delivering bad news. But the study adds to mounting evidence that the brains responses to certain and uncertain threats share deep-rooted connections.

But neuroimaging studies tend to only capture human brains over 20-to-30-second periods, Shackman notes. And rodent brain-scan experiments tend to last only about 10 to 15 minutes per critter. Less is known about what exactly happens in the brain over longer periods of anxiety.

So, the neuroscience behind the pervasive distress common in anxiety disorders is still a work in progress. And no one has spent calendar year 2020 ensconced in a brain scanner (although, given all of the mayhem in the world, perhaps some would have volunteered).

But scientists do know that, as a result of heightened states of anxiety over long periods of time, the brain can change in structure, cells and activity, Addy says. Prolonged anxiety can lead humans to become hypervigilant, where they are anxious when no real threat exists. This is relevant to post-traumatic stress disorder, in which a panic or fear response is triggered in a person who experienced a traumatic event in the past.

In a lot of ways, with everything that happened with Covid throughout the world, its almost as if society, in a sense, is going through a type of collective trauma, Addy says.

Not all anxiety is bad, though. It can be a motivating agent, scientists say. You can channel your jitters from worrying about the future into political action, community building and fighting for the change you want to see. If reading endless streams of news and social media content fuels your worries, try to limit the doomscrolling and instead come up with concrete plans to help your family and community in safe ways, Shackman says.

Having a consistent daily routine is important to reengaging the prefrontal cortex, Addy says, helping to move through waves of emotion and stimulate areas of the brain that calm down your heightened reactions.

Finding activities that get you into a flow state, in which you are fully engaged in the present moment and time seems to pass quickly, can be a great way to get through times of uncertainty, Sweeny says. It might be baking, gardening, competing in video games or playing music. It might not even be recreationalSweeny feels her flow state while doing data analysis.

And dont forget, that, like at a football game, no matter how loud you scream, your emotional reaction isnt going to affect the players performance or the eventual score, Wittmann says. Your anxieties arent going to develop a Covid vaccine, or sway the outcome of the U.S. election.

Those on edge about election results may take some comfort in knowing that, according to Sweeny, anxiety decreases once the outcome arriveseven if its not the result you wanted.

Disappointment and other negative emotions may flood in, of course. But bad news is, in its way, an antidote to anxiety because it squashes uncertainty. The agony of the wait itself evaporates.

It is a relief to just know what were dealing with, Sweeny says.

Read more here:
Anxious About Election Results? Here's What's Happening in Your Brain as You Wait - Smithsonian Magazine